Back to Search
Start Over
ExonHit receives approval for Phase II trial of Alzheimer's.
- Source :
- PharmaWatch: CNS; Feb2008, Vol. 7 Issue 2, p7-7, 1/3p
- Publication Year :
- 2008
-
Abstract
- The article reports that ExonHit Therapeutics has obtained regulatory approval to initiate a Phase II clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. The clinical trial aims to identify the safety and tolerability of the product when it is administered orally for a three-month period in conjunction with an acetylcholinesterase inhibitor.
Details
- Language :
- English
- Volume :
- 7
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- PharmaWatch: CNS
- Publication Type :
- Report
- Accession number :
- 29406314